Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-10-03 Opioid dependence
These products should only be initiated following advice from the drug and alcohol team, or other specialist.
Links
LSCMMG: ADHD combined adult and child shared care guideline- LSCMMG: Opioid reduction: best interests opioid reduction position statement
- LSCMMG: Opioid treatment: patient-prescriber opioid treatment agreement
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug Safety Update Jan 2020: E-cigarette use or vaping: reporting suspected adverse reactions, including lung injury
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Opioids: risk of dependence and addiction
- NICE CG52: Drug misuse in over 16s: opioid detoxification
- NICE TA114: Methadone and buprenorphine for the management of opioid dependence
- NICE TA114: Methadone and buprenorphine for the management of opioid dependence
- NICE TA114: Methadone and buprenorphine for the management of opioid dependence
- NICE TA114: Methadone and buprenorphine for the management of opioid dependence
- NICE TA115: Drug misuse - naltrexone
- NICE TA115: Naltrexone for the management of opioid dependence